Just a week after announcing its intention to launch an IPO in the United States, Cardio3 Biosciences continues increasing its presence in the States. The company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a significant patent application broadly covering TCR-deficient T-Cells engineered to express a chimeric antigen (CAR).
This patent application is the first allowed application in a series of filed patent applications augmenting the company’s protection for its allogeneic T-Cell technology. Cardio3 Biosciences (C3BS) has applied for additional patents related to this technology, which are in various phases of USPTO review. Allogeneic technology has the potential to optimize CAR T-Cell cancer immunotherapies by enabling the manufacturing of off-the-shelf cell products for the treatment of patients without the need for a genetic match.
Dr. Christian Homsy, CEO of Cardio3 BioSciences, commented: “We are extremely pleased to have received the Notice of Allowance from the USPTO for this patent application for TCR-deficient T-Cells engineered to express a CAR, and we are actively pursuing coverage in other countries. To our knowledge, this patent application is the first allowed application regarding TCR-deficient T-Cells suitable for use in allogeneic T-Cell therapies, and we are not aware of any other technology in development for the manufacture of allogeneic T-Cells.“
Cardio3 BioSciences’ lead immune-oncology product candidate, CAR-NKG2D, is a chimeric antigen receptor (CAR) T-Cell autologous therapy to treat cancer. The CAR technology developed by Cardio3 BioSciences uses human natural killer cell (NK cell) receptors which target ligands present on a broad range of solid tumors and blood cancers.
The research underlying this technology was originally conducted by Dartmouth College Professor Charles Sentman, and has been published in numerous peer-reviewed publications such as Journal of Immunology in 2009, Cancer Research in 2006, and Blood in 2005. CAR-NKG2D has an active Investigational New Drug (IND) application with the FDA for a Phase I clinical trial in certain hematologic cancers. The primary objective of this dose escalation trial is to assess safety and feasibility in certain acute myeloid leukemia (AML) and multiple myeloma patients.
Let's Continue The Conversation
Feel free to send us comments about this article to email@example.com and/or comment on that article on social media.